DeepMed Research

The Gynecologic Oncology Group

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1970-01-01

Employees: 11

Market Cap: -

Website: http://www.gog.org

Clinical Trials

Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer

Phase 2

Completed

Conditions: Uterine Carcinosarcoma
Recurrent Uterine Corpus Sarcoma

Interventions: Drug: Gemcitabine Hydrochloride
Drug: Docetaxel

First Posted Date: 2005-06-14

Last Posted Date: 2019-01-08

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 28

Registration Number: NCT00114218

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer

Phase 2

Completed

Conditions: Sarcoma

Interventions: Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2005-06-03

Last Posted Date: 2018-09-25

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 55

Registration Number: NCT00112489

Locations: 🇺🇸
Fox Chase Cancer Center CCOP Research Base, Philadelphia, Pennsylvania, United States
🇺🇸
Mount Carmel Health - West Hospital, Columbus, Ohio, United States
🇺🇸
Case Comprehensive Cancer Center, Cleveland, Ohio, United States

and more 107 locations

Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer

Phase 1

Completed

Conditions: Cervical Adenocarcinoma
Stage IB Cervical Cancer
Cervical Adenosquamous Carcinoma
Cervical Small Cell Carcinoma
Stage III Cervical Cancer
Stage IIA Cervical Cancer
Stage IIB Cervical Cancer
Cervical Squamous Cell Carcinoma
Stage IVA Cervical Cancer

Interventions: Radiation: Internal Radiation Therapy
Radiation: 3-Dimensional Conformal Radiation Therapy
Biological: Cetuximab
Drug: Cisplatin

First Posted Date: 2005-03-04

Last Posted Date: 2014-12-31

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 64

Registration Number: NCT00104910

Locations: 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
Georgia Regents University Medical Center, Augusta, Georgia, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

and more 12 locations

Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Phase 2

Completed

Conditions: Cervical Cancer

First Posted Date: 2005-01-10

Last Posted Date: 2014-03-17

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 76

Registration Number: NCT00101192

Locations: 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
University of Mississippi Cancer Clinic, Jackson, Mississippi, United States
🇺🇸
Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, United States

and more 15 locations

Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma

Phase 2

Completed

Conditions: Sarcoma

First Posted Date: 2005-01-10

Last Posted Date: 2014-02-14

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00101127

Locations: 🇺🇸
Kaiser Permanente Medical Center - Los Angeles, Los Angeles, California, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Drexel University College of Medicine - Center City Hahnemann Campus, Philadelphia, Pennsylvania, United States

and more 57 locations

Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational Trophoblastic Tumor After a Molar Pregnancy

Phase 2

Terminated

Conditions: Gestational Trophoblastic Tumor

First Posted Date: 2004-11-09

Last Posted Date: 2018-04-12

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 55

Registration Number: NCT00096187

Locations: 🇺🇸
CCOP - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸
St. John's Regional Health Center, Springfield, Missouri, United States
🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States

and more 22 locations

Combination Chemotherapy in Treating Patients With Recurrent or Advanced Cancer of the Uterus

Phase 2

Terminated

Conditions: Sarcoma

First Posted Date: 2004-09-03

Last Posted Date: 2013-07-09

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 30

Registration Number: NCT00002993

Locations: 🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

and more 51 locations

Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer

Phase 1

Terminated

Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2004-08-26

Last Posted Date: 2013-07-09

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 45

Registration Number: NCT00003378

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States

and more 61 locations

Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer

Phase 3

Completed

Conditions: Endometrial Cancer
Psychosocial Effects of Cancer and Its Treatment

First Posted Date: 2004-08-23

Last Posted Date: 2014-02-14

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00002493

Locations: 🇺🇸
Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, District of Columbia, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States

and more 55 locations

Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

Phase 1

Terminated

Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer
Fallopian Tube Cancer

First Posted Date: 2004-08-16

Last Posted Date: 2013-06-10

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00003380

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States

and more 60 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy